SUVEN

SUVEN LIFE SCIENCES: TO PRESENT 5 SCIENTIFIC POSTERS AT AAIC 2026 🧠🔬 • 🌍 Suven Life Sciences will present 5 scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12–15. • 🧪 Key presentations include updates on the Global Phase-3 Masupirdine program for agitation in Alzheimer's dementia and the Phase-2 Usmarapride clinical development program. • 📊 The company will also present research on SUVN-I6107, SUVN-L1101142, and SUVN-N9503012, strengthening its CNS pipeline visibility. • 🤝 Suven will engage with global researchers, investigators, key opinion leaders, and explore strategic partnering opportunities for its neuroscience portfolio. • 🧬 The company currently has 5 clinical-stage assets and 7 research-stage programs targeting Alzheimer's, Parkinson's, depression, schizophrenia, sleep disorders, cognitive disorders, and pain. 🟢 Impact: Positive (Highlights the progress of Suven's clinical pipeline, enhances global visibility, and could support future licensing or partnership opportunities.)